SCHEMBL3103270

SCHEMBL3103270

Cc1c(COc2cccc(OCC3CCOCC3)c2)[nH]c2ccc(-c3ccccc3C(=O)O)cc2c1=O

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 8/20 0.70
BRS3 P32247 1/20 0.40
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SLC16A3 O15427 1/20 0.37
SLC16A1 P53985 1/20 0.37
MCTS1 Q9ULC4 1/20 0.37
DHODH Q02127 3/20 0.37
DGAT1 O75907 1/20 0.36
GSK3B P49841 1/20 0.36
CNR1 P21554 3/20 0.36
CNR2 P34972 3/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3096589 0.92 CYP2D6 (0.67) CYP2D6KDM4ELMNAMAPTHPGD
SCHEMBL13097967 0.86 CYP2D6 (0.75) CYP2D6KDM4ELMNAMAPTHPGD
SCHEMBL13097573 0.83 CYP2D6 (0.82) CYP2D6KDM4ELMNAMAPTHPGD
SCHEMBL3101982 0.83 CYP2D6 (1.00) CYP2D6KDM4ELMNAMAPTHPGD
SCHEMBL13097596 0.82 CYP2D6 (0.85) CYP2D6GSK3B
SCHEMBL13097574 0.82 CYP2D6 (0.79) CYP2D6KDM4ELMNAMAPTHPGD
SCHEMBL13097576 0.82 CYP2D6 (0.79) CYP2D6SLC16A3SLC16A1MCTS1PDE3B
SCHEMBL13097571 0.82 CYP2D6 (0.79) CYP2D6KDM4ELMNAMAPTHPGD
SCHEMBL13097570 0.82 CYP2D6 (0.79) CYP2D6KDM4ELMNAMAPTHPGD
SCHEMBL13097583 0.81 CYP2D6 (1.00) CYP2D6GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367702-B2 Quinolone derivative ASTELLAS PHARMA INC. (JP) 2013-02-05 US disclosed
US-20100256113-A1 QUINOLONE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-10-07 US disclosed
EP-2194044-A1 QUINOLONE DERIVATIVE Astellas Pharma Inc. (JP) 2010-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256113-A1 QUINOLONE DERIVATIVE NQO1, NQO2, NADK CYP2D6 230/4885BRS3 4095/4885KDM4E 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.